Valuation: Glenmark Pharmaceuticals Limited

Market Cap 73TCr 777.53Cr 697.37Cr 637.34Cr 581.79Cr 1.1TCr 1.13TCr 7.68TCr 3.06TCr 39TCr 2.92TCr 2.86TCr 1,23100Cr P/E 2027 *
31.6x
P/E 2028 * 26.1x
Enterprise Value 70TCr 739.5Cr 663.26Cr 606.16Cr 553.33Cr 1.04TCr 1.08TCr 7.31TCr 2.91TCr 37TCr 2.78TCr 2.72TCr 1,17100Cr EV / Sales 2027 *
4.1x
EV / Sales 2028 * 3.65x
Free-Float
51.04%
Yield 2027 *
0.15%
Yield 2028 * 0.16%
1 day-0.34%
1 week+8.36%
Current month+12.29%
1 month+17.74%
3 months+14.65%
6 months+9.08%
Current year+26.83%
1 week 2,306
Extreme 2306
2,682.5
1 month 2,101.6
Extreme 2101.6
2,682.5
Current year 1,842
Extreme 1842
2,682.5
1 year 1,807
Extreme 1807
2,682.5
3 years 722.1
Extreme 722.1
2,682.5
5 years 348.5
Extreme 348.5
2,682.5
10 years 161.65
Extreme 161.65
2,682.5
Manager TitleAgeSince
Chief Executive Officer 57 01/01/2000
President - 15/09/2023
President - -
Director TitleAgeSince
Director/Board Member 61 14/08/2020
Director/Board Member 68 14/08/2025
Director/Board Member 71 14/02/2025
Change 5-day change 1-year change 3-year change Capi.($)
-0.12%+8.36%+41.06%+228.42% 777.53Cr
-0.79%-4.48%+46.48%+125.69% 1,20600Cr
+1.43%+1.11%+48.05%+83.05% 66TCr
+1.07%-1.21%+32.92%+104.92% 51TCr
-0.36%-3.25%+45.42%+65.10% 38TCr
-0.14%-1.87%+70.06%+41.09% 36TCr
-0.78%-0.52%+30.47%+58.09% 31TCr
-0.80%-0.21%+7.98%+36.17% 29TCr
+0.03%-1.20%+43.79%+69.83% 25TCr
-0.41%-2.22%+40.43%+107.03% 21TCr
Average -0.11%-0.12%+40.67%+91.94% 41.88TCr
Weighted average by Cap. -0.05%-1.93%+42.71%+88.37%

Financials

2027 *2028 *
Net sales 17TCr 180.31Cr 161.72Cr 147.8Cr 134.92Cr 254.19Cr 262.2Cr 1.78TCr 710.36Cr 9.04TCr 676.79Cr 662.27Cr 29TCr 19TCr 199.26Cr 178.72Cr 163.33Cr 149.1Cr 280.91Cr 289.77Cr 1.97TCr 785.03Cr 9.99TCr 747.93Cr 731.89Cr 32TCr
Net income 2.37TCr 25Cr 23Cr 21Cr 19Cr 36Cr 37Cr 249.04Cr 99Cr 1.26TCr 95Cr 93Cr 3.99TCr 2.83TCr 30Cr 27Cr 25Cr 23Cr 42Cr 44Cr 297.68Cr 118.7Cr 1.51TCr 113.09Cr 110.66Cr 4.77TCr
Net Debt -3.57TCr -38Cr -34Cr -31Cr -28Cr -54Cr -55Cr -375.75Cr -149.83Cr -1.91TCr -142.75Cr -139.69Cr -6.02TCr -4.72TCr -50Cr -45Cr -41Cr -38Cr -71Cr -73Cr -495.7Cr -197.66Cr -2.52TCr -188.32Cr -184.28Cr -7.94TCr
Projected Income Statement - Annual - Glenmark Pharmaceuticals Limited
Logo Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company’s offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. It is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.
Employees
16,946
Date Price Change Volume
08/26/08 ₹2,587.00 -0.12% 71,766
06/26/06 ₹2,590.00 +4.36% 50,36,760
05/26/05 ₹2,481.80 -0.91% 9,01,870
04/26/04 ₹2,504.70 +4.02% 7,17,669
03/26/03 ₹2,408.00 +1.09% 9,30,049
Trader
Investor
Global
Quality
ESG MSCI
BB
MarketScreener Ratings - Glenmark Pharmaceuticals Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
2,590.00INR
Average target price
2,512.82INR
Spread / Average Target
-2.98%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Glenmark Pharmaceuticals Limited
  1. Stock Market
  2. Stocks
  3. GLENMARK Stock